Tubeless Insulin Pump Market, By Component (Pod/Patch, Remote, and Others), By Distribution Channel (Hospitals, Pharmacies, e-Commerce, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

Tubeless Insulin Pump Market was valued at US$ 1.87 Billion in 2024 and is projected to grow at a CAGR of 21.30% to reach US$ 12.6 Billion by 2034.

Tubeless insulin pumps are discreet, small, and lightweight in nature and are also known by the name of insulin patch pumps. These are preferred and used by type 1 diabetes patients.

The rising prevalence of diabetes across the world is expected to drive the growth of the target market. The constant progression of chronic conditions like diabetes is due to certain other factors, like obesity and the ageing population, which in turn is boosting the growth of the Tubeless Insulin Pump Market.  For instance, in 2015, according to the National Diabetes Statistics, it was reported that almost 30.3 million people across the U.S. had been suffering from diabetes.

Rising Technological Advancements to fuel the target market growth

The increasing technological advancements and improved developments are responsible for the increase in the growth of the Tubeless Insulin Pump Market. Over the past several years, a variety of insulin pump technologies with increased patient comfort and better treatment of hyperglycemia and hypoglycemia episodes have been introduced. The development of the market for these insulin pumps, particularly tubeless pumps, has been largely influenced by shifting regulatory environments and clearly ongoing technological developments. Automation of continuous insulin delivery systems has revealed unquestionably great possibilities. The market for tubeless insulin pumps has experienced new growth trajectories as a result of medical device manufacturers' tenacious attempts to give patients more options. Additionally, compared to multiple-dose insulin injections, the use of tubeless insulin pumps has improved quality of life measurements, eventually leading to the growth of the Tubeless Insulin Pump Market.

For instance, in January 2022, Insulet’s “Omnipod 5” received FDA (Food and Drug Administration) approval which is the latest, tubeless insulin pump incorporated with a hi-tech system which never sleeps.

Furthermore, the San Diego-based maker of insulin pumps has set up a goal of reaching at most 1 million users by the year 2027 by expanding it to the patients with Type 2 diabetes.

 

Numerous Benefits to the users to boost the target market growth

The various benefits provided by these pumps to patients is another major factor leading to the growth of the Tubeless Insulin Pump Market. The use of a tubeless insulin pump reduces the need for daily insulin injections and improves blood glucose level management. It is portable, convenient, and effective. Benefits like reduced discomfort and more convenient insulin administration will be the main determinants of increased product choice. Devices include the Omni Pod, a revolutionary tubeless insulin pump that schedules insulin administration, shows blood glucose levels, and determines the best insulin dosage based on a dietary database. Patient compliance with diabetes treatment has increased as non-invasive transdermal insulin delivery methods have become more widely used. The penetration of insulin through the transdermal route has also improved with the use of microneedles and microemulsions, eventually leading to the growth of the Tubeless Insulin Pump Market.

Restrains:

The increased risk of diabetic ketoacidosis in patients is the major factor restraining the growth of the Tubeless Insulin Pump Market. If the pump fails, the patient has a considerable risk of developing diabetic ketoacidosis. This may occur when the battery drains, when heat exposure inactivates the insulin, or when the tank is empty. In these situations, the catheter kinks to prevent the administration of insulin or spills insulin which in turn leads to the patient dealing with several problems as a result, including skin conditions which in turn hamper the Tubeless Insulin Pump Market growth.

For instance, in February 2021, according to a study published in PubMed Central, it was reported that insulin pumps, compared to injections, failed to predict a lower incidence of DKA (Diabetic ketoacidosis) in the patients. In order to compare the risk of DKA (Diabetic ketoacidosis) between insulin injections and insulin pumps in the US, scientists performed a retrospective cohort research. The Agency for Healthcare Resources and Quality (AHRQ) carefully selected these hospitalizations and included all type 1 diabetes mellitus patients over the age of 18 who were taking insulin, either by pump or injection. In conclusion, they identified 58,260 hospitalizations for type 1 diabetes patients in total. Among them, 7850 utilized an insulin pump, 30,672 injected insulin, and 19,738 had never used insulin before. They concluded that the insulin pumps in comparison to the injections, failed to predict a lower incidence of DKA (Diabetic ketoacidosis).

 

Component Insight

On the basis of Component, Tubeless Insulin Pump Market is segmented into Pod/Patch, Remote, and Others. The Pod/Patch component segment is expected to dominate the growth of the target market due to their increasing adoption among the diabetic population in numerous developed countries.

Distribution Channel Insights

On the basis of Distribution Channel, Tubeless Insulin Pump Market is segmented into Hospitals, Pharmacies, e-Commerce, and Others. The Pharmacies distribution channel segment is expected to dominate the growth of the target market owing to the growing availability of various diabetes management devices in the retail sector.

Regional Insights

On the basis of Region, the Tubeless Insulin Pump Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North American market is expected to dominate the growth of the target market over the forecast period owing to the increasing rate of awareness of the people regarding the use of tubeless insulin pumps, rising geriatric as well as diabetic population, growing research and development activities in numerous healthcare bodies. All these factors are anticipated to increase the demand for the Tubeless Insulin Pump Market in the region.

Attribute Details Base year for estimation 2023 Forecast period 2024 – 2034 Market representation Revenue in USD Billion & CAGR from 2024 to 2034 Market Segmentation By Component - Pod/Patch, Remote, and Others By Distribution Channel - Hospitals, Pharmacies, e-Commerce, and Others Regional scope North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa Report coverage Revenue forecast, company share, competitive landscape, growth factors, and trends Segments Covered in the Report: This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the Tubeless Insulin Pump Market report based on Component, Distribution Channel, and Region: Tubeless Insulin Pump Market, By Component: Pod/Patch Remote Others Tubeless Insulin Pump Market, By Distribution Channel: Hospitals Pharmacies E-Commerce Others By Region: North America U.S. Canada Europe Germany UK France Russia Italy Rest of Europe Asia Pacific China India Japan South Korea Rest of Asia Pacific Latin America Brazil Mexico Rest of Latin America Middle East & Africa GCC Israel South Africa Rest of Middle East & Africa

The key players operating the Tubeless Insulin Pump Market includes, Insulet Corporation, Johnson & Johnson, Medtrum Technologies, Inc. Roche Holding AG, Cellnovo Group SA, Spring Health Solution Ltd., Debiotech SA, CeQur SA, Valeritas Holdings, Inc., and Abbott Diabetes Care, Inc.

Recent Development:

• In April 2023, DUBLIN received FDA (Food and Drug Administration) approval for one of its successful products, the ‘MiniMed 780G’ system with the Guardian 4 sensor with no requirement of fingersticks while in SmartGuard technology. This is the only system that also has meal detection technology, which in turn provides automatic adjustments for the sugar level every 5 minutes.
• In January 2022, Insulet received FDA (Food and Drug Administration) approval for its "Omnipod 5", the only tubeless patch pump, that never sleeps. It functions day and night and also gives protection against the highs and lows of insulin.
• In March 2021, Insulet Corporation declared positive results for the pivotal trials which were conducted for the Omnipod 5 Automated Insulin Delivery System. This is a wearable system that adjusts insulin delivery depending on the glucose levels in human being.

• Insulet Corporation*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Johnson & Johnson
• Medtrum Technologies, Inc.
• Roche Holding AG
• Cellnovo Group SA
• Spring Health Solution Ltd.
• Debiotech SA
• CeQur SA
• Valeritas Holdings, Inc.
• Abbott Diabetes Care, Inc.

“*” marked represents similar segmentation in other categories in the respective section

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Study Scope
   • Years Considered for the study
   • Assumptions
   • Abbreviations
2. Research Methodology
   • Research data
   • Primary Data
     • Primary Interviews
     • Primary Breakdown
     • Key data from Primary Sources
     • Key Thickness Insights
   • Secondary Data
     • Major Secondary Sources
     • Secondary Sources
   • Market Estimation
   • Top-Down Approach
     • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
   • Bottom-Up Approach
     • Approach for estimating market share by Bottom-up Analysis (Demand Side)
   • Market Breakdown and Data Triangulation
   • Research Assumptions
3. Market Preview
   • Executive Summary
   • Key Findings—Global Outlook for medical carts Strategies
     • Key Questions this Study will Answer
     • Market Snippet, By Component
     • Market Snippet, By Distribution Channel
     • Market Snippet, By Region
   • Opportunity Map Analysis
   • Executive Summary—3 Big Predictions
4. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restrains
     • Market Opportunities
     • Market Trends
   • DR Impact Analysis
   • PEST Analysis
   • Porter’s Five Forces Analysis
   • Opportunity Orbit
   • Market Investment Feasibility Index
   • Macroeconomic Factor Analysis
5. Tubeless Insulin Pump Market, By Component
   • Overview
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
     • Y-o-Y Growth Analysis (%), 2022 – 2032
     • Segment Trends
   • Pod/Patch
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
   • Remote
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
   • Others
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
6. Tubeless Insulin Pump Market, By Distribution Channel, 2022 – 2032, (US$ Bn)
   • Overview                                      
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
     • Y-o-Y Growth Analysis (%), 2022 – 2032
     • Segment Trends
   • Hospitals
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
   • Pharmacies
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
   • e-Commerce
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
   • Others
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
7. Tubeless Insulin Pump Market, By Region, 2022 – 2032, (US$ Bn)
   • Overview
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
     • Y-o-Y Growth Analysis (%), 2022 – 2032
     • Regional Trends
   • North America
     • Market Size and Forecast (US$ Bn), By Component, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By Distribution Channel, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
       • U.S.
       • Canada
   • Europe
     • Market Size and Forecast (US$ Bn), By Component, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By Distribution Channel, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
       • UK
       • France
       • Germany
       • Russia
       • Italy
       • Rest of Europe
   • Asia Pacific
     • Market Size and Forecast (US$ Bn), By Component, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By Distribution Channel, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
       • India
       • Japan
       • South Korea
       • China
       • Rest of Asia Pacific

• • Latin America
    • Market Size and Forecast (US$ Bn), By Component, 2022 – 2032
    • Market Size and Forecast (US$ Bn), By Distribution Channel, 2022 – 2032
    • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
• • • • Brazil
      • Mexico
      • Rest of Latin America
  • Middle East & Africa
    • Market Size and Forecast (US$ Bn), By Component, 2022 – 2032
    • Market Size and Forecast (US$ Bn), By Distribution Channel, 2022 – 2032
    • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032

1. • • • GCC
       • Israel
       • South Africa
       • Rest of Middle East
2. Competitive Landscape
   • Heat Map Analysis
   • Market Presence and Specificity Analysis
3. Company Profiles

• Insulet Corporation
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Johnson & Johnson
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Medtrum Technologies, Inc. 
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Roche Holding AG
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Cellnovo Group SA
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Spring Health Solution Ltd.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Debiotech SA
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• CeQur SA
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Valeritas Holdings, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Abbott Diabetes Care, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

1. The Last Word
   • Future Impact
   • About Us
   • Contact